FDA oncology division director
FDA appoints Robert Justice as director of the Division of Drug Oncology Products within FDA's Office of Oncology Drug Products, effective June 11. Justice had been acting director of the division since it became operational as part of a July 2005 CDER reorganization (1"The Pink Sheet" June 27, 2005, p. 11). Justice has held several positions within the agency since 1985 and was a senior clinical scientist at Genentech from 2000-2002...
You may also be interested in...
Deputy director of FDA's biological oncology product review team Robert Justice will head the Division of Drug Oncology Products under the reorganization of the Office of New Drugs
Pink Sheet Podcast: COVID Vaccine In Adolescents, CMS Drug Pricing Moves, Standard Care In Clinical Trials
Pink Sheet reporters and editors discuss the US FDA decision to lower the eligibility age for the Pfizer/BioNTech COVID-19 vaccine, CMS drug pricing project plans, and mid-stream standard of care changes in drug development.
Keeping Track: US FDA Approves Heron’s Zynrelef In Post-Op Pain; Amgen/AZ Submit Tezepelumab For Severe Asthma
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker